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FATE and TPTE genes were originally reported to be specifically expressed in the adult testis. We searched for the databases of
Unigene and serial analysis of gene expression (SAGE) implying that these two gene transcripts might also be expressed in tumours.
Herein, we demonstrated that FATE and TPTE mRNA transcripts were expressed in different histological types of tumours and
normal testis. Both are cancer-testis (CT) antigens and renamed as FATE/BJ-HCC-2 and TPTE/BJ-HCC-5, respectively. Comparison
at nucleotide sequence, the FATE/BJ-HCC-2 cDNA, was identical to that of FATE, whereas the TPTE/BJ-HCC-5 was found to have
two isoforms in both cancers and testis: one was identical in cDNA sequence to TPTE, encoding a protein of 551 amino acids, and
the other variant lacked an exon of 54bp, encoding a protein of 533 amino acids. The mRNA expression was analysed by RT–PCR
and real-time PCR. FATE/BJ-HCC-2 mRNA was detected in 66% (41 out of 62) in hepatocellular carcinoma (HCC) samples and 21%
(three out of 14) in colon cancer samples, whereas the TPTE/BJ-HCC-5 mRNA was detected in 39% (24 out of 62) and 36% (five
out of 14) in HCC and non-small lung cancer samples, respectively. The recombinant proteins were prepared and the reactivity of
allogenic sera to these two antigens was screened. The frequency of antibody response against FATE/BJ-HCC-2 and TPTE/BJ-HCC-5
proteins was 7.3% (three out of 41) and 25.0% (six out of 24), respectively, in HCC patients bearing respective gene transcripts.
Therefore, FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 are the novel CT antigens capable of eliciting antibody response in cancer patients.
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Hepatocellular carcinoma (HCC) is one of the most common and
severe diseases in the world (Okuda, 1992). Although there are
many established therapeutic methods including surgery, che-
motherapy, radiotherapy, ethanol injection therapy, and transar-
terial embolisation, the therapeutic results remain unsatisfactory
due to late diagnosis.
The identification of tumour-associated antigens recognised by
cellular and/or humoral effectors of the immune system has
provided new perspectives for tumour therapy. A variety of
tumour-associated antigens have been identified, including:
cancer-testis (CT) antigens, which are expressed in different
histological types of tumours, but not in normal tissues except
testis, differentiation antigens, viral antigens, mutated antigens,
and the products of overexpressed genes. Of all the antigens
identified, the CT antigens are the most attractive targets for
vaccination in tumour immunotherapy with the potential to
eradicate residual tumour cells in multiple sites in the body. In
vitro and in vivo experiments have demonstrated that some CT
antigens, for example, NY-ESO-1, are capable of provoking potent
T-cell-mediated immunity to directly kill tumour cells and/or
release cytokines to interfere with the growth and propagation of
tumour cells (Jager et al, 2001; Kirkin et al, 2002).
To date, a growing number of antigens have been cloned and
identified by various approaches, such as SSX2 and NY-ESO-1 by
SEREX (Sahin et al, 1995; Chen et al, 1997b; Gu ¨re et al, 1997),
CT10 and SAGE (sarcoma-associated antigen) by RDA (Gu ¨re et al,
2000; Martelange et al, 2000), and CTp11 by differential mRNA
expression (Zendman et al, 1999). Only a minority of the identified
tumour antigens are immunogenic with the potential for
immunotherapy. A crucial factor alleviating the efficacy of tumour
immunotherapy is the immunoselection that occurs in the
vaccination process and resulted in the progressive loss of tumour
antigens together with the downregulation of HLA proteins
(Giorgio et al, 2002). To improve the efficacy of tumour vaccines
and prevent immune escape, further identification of novel CT
antigens is warranted in order to develop applicable polyvalent
tumour vaccines.
In this paper, we described two novel CT antigens identified by
the analysis of databases and confirmed by experiments, termed
FATE/BJ-HCC-2 and TPTE/BJ-HCC-5, respectively. Both of them
are expressed, at a high percentage, in HCC and in some other
types of tumours. The antibodies against these two antigens were
detected in the sera of a minor proportion of HCC patients. It
supports the fact that both CT antigens are immunogenic in cancer
patients.
MATERIALS AND METHODS
Human tumour tissues and sera
All samples of human HCC, colon cancer, gastric cancer, and non-
small cell lung cancer tissue and paired noncancerous tissue (5cm
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yaway from tumour) were obtained during surgical resection from
our 2nd Teaching Hospital, Peking University Health Science
Center. Patients agreed to collection of tissue samples and sera
with written consent and this was permitted by Hospital Ethic
Review Committee. The resected tissue samples were immediately
cut into small pieces, then, snap-frozen in liquid nitrogen until use.
All tumour tissue and paired noncancerous tissue samples were
pathologically confirmed. The patients from whom the resected
HCC samples were obtained were HBV surface antigen positive,
but HCV antigen negative.
Unigene and SAGE databases analysis
Unigene is an experimental system for automatically partitioning
GenBank sequences into a nonredundant set of gene-oriented
clusters. Each Unigene cluster contains sequences that represent a
Unigene gene, as well as the related information such as the tissue
types in which the gene has been expressed and hundreds of
thousands of expressed sequence tag (EST) sequences in which the
tissue types are labelled (Schuler, 1997). Serial analysis of gene
expression (SAGE) is an on-line technique that allows us to obtain
a quantitative and comprehensive cellular gene expression profile
(Velculescu et al, 1995). Consequently, Unigene and SAGE can be
used to analyse the spatial and temporal expression pattern of a
given gene for predicting the functional information of the gene.
RT–PCR
The mRNA expression pattern was assayed by RT–PCR using
panels of commercially available cDNA (Clontech, Palo Alto, CA,
USA). One panel is comprised of 16 normal tissues: brain, heart,
kidney, liver, lung, pancreas, placenta, skeletal muscle, colon,
ovary, peripheral blood leucocyte, prostate, small intestine, spleen,
testis, and thymus. RNA from HCC, paired adjacent noncancerous
liver tissues and cancer tissues of lung, colon, and stomach was
extracted, and reversely transcribed with Advantage reverse
transcriptase (Clontech, Palo Alto, CA, USA). Gene-specific PCR
primers were used to amplify cDNA fragments of FATE/BJ-HCC-2
and TPTE/BJ-HCC-5. RT–PCR was performed using the following
parameters: FATE/BJ-HCC-2, 30 cycles, 941C, 15s; 681C, 30s; and
721C, 30s, followed by 6min extension at 721C; TPTE/BJ-HCC-5,
30 cycles, 941C, 15s; 651C, 30s; and 721C, 1.5min, followed by
6min extension at 721C. The sequence of paired primers for the
amplification of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 was: FATE/
BJ-HCC-2, forward: ctg ttc ctg gca ccc tgt gca tcc; reverse: gat gcc
gcc atg ctg ttc acc c; TPTE/BJ-HCC-5, forward: cca caa tgg tcc acc
cac aaa tg; reverse: aac atg tgg cag ggt tgg aaa gaa c.
Quantification of gene expression
Quantification of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 expression
was performed by monitoring the increase in fluorescence by the
binding of SYBR green to double-stranded DNA during real-time
PCR (Schmittgen et al, 2000). Their specific amplification primers
were described above. All reactions were carried out in triplicate
with positive and negative controls using the standard programme.
Melt-curve analysis was performed to determine the temperature
at which data were collected. For the data collection step in real-
time PCR, after incubation at 501C for 2min, denaturing at 951C
for 10min, the PCR parameters for FATE/BJ-HCC-2 were 40 cycles
of 951C, 15s, 681C, 1min, and 861C, 10s; and the parameters for
TPTE/BJ-HCC-5 were 40 cycles of 951C, 15s, 651C, 2min, and
881C, 10s. Gene expression level was measured by the quantifica-
tion of cDNA relative to normal testis (Clontech, Palo Alto, CA,
USA) serving as a calibrator sample and G3PDH gene was used as
an endogenous control. To analyse the relative quantification for a
target gene, the following data were required: the mean CT value of
the replicate wells running for each sample; the difference (DCT)
between the mean CT value of the samples for the target gene and
of the samples for the endogenous controls; the difference (DDCT)
between the DCT values of the samples for each target and the
mean CT value of the calibrator for that target gene. The relative
quantification value was expressed as 2 DDCT.
Northern blot analysis
Northern blots were performed with mRNA samples extracted
from HCC and paired adjacent non-HCC liver tissues. RNA
integrity was examined by electrophoresis in formalin/4-morpho-
line propane sulphonic acid gels. mRNA (2mg) per lane was first
separated by electrophoresis in 1.2% agarose containing 3%
formaldehyde and then blotted onto nylon membranes (Amer-
sham Hybond-C, USA). The membranes were crosslinked under
ultraviolet radiation. The DIG-labelled probes were the cDNA
sequences of FATE/BJ-HCC-2 (506bp) and TPTE/BJ-HCC-5
(1048bp). After prehybridization, the membranes were hybridised
to the specific DIG-labelled probes overnight at 421Ci n
hybridisation solution (50% formamide, 5XSSC, 0.1% N-lauroyl-
sarcosine, 0.02% SDS, 2% blocking reagent, and 100mgml
 1
sheared salmon sperm DNA). Filters were then sequentially
washed at room temperature for 30min in 0.1% SDS, 2XSDS,
and at 681C for 30min in 0.1% SDS and 0.1XSDS. After stringent
washes, the corresponding mRNA in Northern blot was detected
by chemiluminescence using CSPD ready-to-use reagent (Roche,
Indianapolis, USA).
Expression and purification of FATE/BJ-HCC-2 in E. coli
The fragment of ORF of FATE/BJ-HCC-2 was amplified with the
template of the plasmid containing full-length cDNA and the
primers of 50-gcg gca tgc atg gca gga ggc cct ccc-30 and 50-gcg aag
ctt tca ctg gtt cat cca cag cc-30. The amplified products were
digested with SphI and HindIII, and the fragment was inserted into
the expression plasmid pQE30, then, sequenced. The plasmid
pQE30/FATE/BJ-HCC-2 was transformed into E. coli M15. After
induction by 1mM IPTG at 371C for 6h, the produced protein was
purified by Ni
2þ affinity chromatography, as the pQE30 expres-
sion plasmid encodes a 6  His tag at the NH2-terminus.
Expression and purification of TPTE/BJ-HCC-5 in insect
cells
TPTE/BJ-HCC-5A and TPTE/BJ-HCC-5B cDNAs with BamHI and
HindIII restriction sites were cloned into the donor plasmid
pFASTHTb. The recombinant plasmids pFASTHTb/TPTE/BJ-
HCC-5A and pFASTHTb/TPTE/BJ-HCC-5B were introduced into
competent cells DH10Bac. Recombinant bacmids were constructed
by transposing a mini-Tn7 element from the donor plasmid
pFASTHTb/TPTE/BJ-HCC-5A and pFASTHTb/TPTE/BJ-HCC-5B
to the mini-attTn7 attachment site on the bacmids, where the Tn7
transposition function was provided in trans by a helper plasmid
pMON7124. The bacmids were extracted, and transfected into sf9
insect cells to obtain recombinant baculvirus. Infection of sf9
insect cells was carried out in a serum-free medium of SFM at an
m.o.i. of 10. Western blot (WB) analysis with anti-6 His tag mAb
was used to confirm the expression of recombinant TPTE/BJ-HCC-
5A and TPTE/BJ-HCC-5B proteins fused with 6 His tag. The
purification of recombinant proteins was performed by Ni
2þ
affinity chromatography.
Survey of the humoral immune response against
FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 antigens in the
patients of hepatocellular carcinoma
The survey of the humoral immune response against FATE/BJ-
HCC-2 and TPTE/BJ-HCC-5 antigens in HCC patients was
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linked immunosorbent assay (ELISA).
Western blot
Briefly, crude extracted FATE/BJ-HCC-2 and TPTE/BJ-HCC-5
proteins were separated on 10% SDS–polyacrylamide gel electro-
phoresis and transferred onto nitrocellulose membranes. After
blocking with the TNT solution containing 5% dry milk, the
membranes were sequentially incubated with HCC patients’ sera
diluted in 1:1000 for 1.5h, then, incubated with goat anti-human
IgG (HþL) alkaline phosphatase conjugate (Promega, Madison,
WI, USA) for 1h, and colour substrate NBT/BCIP (Promega) was
added for 20-min colour development. The antibody-positive sera
were further tested using purified recombinant proteins as
antigens for verification. To test the specificity of Ab response
against FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 proteins, the irrele-
vant proteins of BJ-9 expressed in E. coli and HCA587 expressed in
insect cells were applied in WB assay using the HCC patient’s sera,
in which the antibody was detected against FATE/BJ-HCC-2 or
TPTE/BJ-HCC-5, but not to BJ-9 or HCA587 (Wang et al, 2002).
Mock-transfected E. coli and insect cell lysates were used in WB as
negative controls.
ELISA
Recombinant proteins of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 at
a concentration of 1mgml
 1 in coating buffer (15mM Na2CO3,
30mM NaHCO3, pH 9.6 with 0.02% NaN3) were absorbed onto 96-
well Munc-Immuon plates (Nunc. Polysorp, Denmark) at 100ml
per well overnight at 41C, respectively. Plates were washed with
0.05% Tween-20/PBS and blocked for 1h at room temperature
(RT) with 100ml per well of 2% BSA–PBS. After washing, 100ml
per well of a serial dilution of serum in 2% BSA–PBS was added
and incubated for 2h at 371C in a water-saturated incubator. Plates
were washed and 100ml per well diluted secondary Ab in 2% BSA–
PBS was added (Goat anti-human IgG-AP: Southern Biotechnol-
ogy, Birmingham, AL, USA) and incubated for 1h at 371C. Plates
were washed, incubated with 100ml per well of substrate solution
(p-nitrophenyl phosphate, Sigma-Aldrich, Inc., USA) for 20–
30min at RT, then the reaction was stopped by adding 3 N NaOH
50ml per well and immediately read at 410nm (ELISA Reader, BIO-
RAD, M550, USA). For the serological survey of human sera, the
serum of melanoma patient NW29 was used as a positive control
for NY-ESO-1 and also as a negative control for MAGE-1 (provided
by Ludwig institute for Cancer Research, NY, USA). All the sera
were tested over a range of serial four-fold dilution from 1:100 to
1:102400. A positive reaction is defined as an OD value of a 1:400
diluted serum that exceeds the mean OD value of negative control
(coated with irrelevant protein) by 3 s.d.
RESULTS
Databases analysis
In our analysis, three criteria were used to limit the candidate
genes. First, the candidate genes are definitely testis-specific, but
they have not been reported to be expressed in tumours. Second,
there must have been ESTs expressed in tumours for the candidate
genes in the Unigene database. Third, if there are SAGE tags for the
sequences of the candidate genes, only the tags absolutely
corresponding to the candidate genes are included, because there
are lots of SAGE tags that are not only homologous to the
candidate genes but also represent other genes.
When these criteria were applied, two genes were found to be
the most promising candidates for CT antigen-encoding genes:
fetal and adult testis expressed transcript (FATE) and transmem-
brane phosphatase with tensin homology (TPTE). Both of them are
known as testis-specific genes. In the database of Unigene, there
were 33 and 47 ESTs representing FATE and TPTE, respectively.
Although most of these ESTs were identified from the libraries of
testis, two ESTs for FATE were derived from adrenal gland
carcinoma and adrenal cortico-adenoma for Cushing’s syndrome,
and four ESTs for TPTE derived from adrenal gland carcinoma,
uterus tumour and colon cancers. In the SAGE database, two tags
representing TPTE were identified from the libraries of brain
glioblastoma multiform cell line and ovary carcinoma, although no
tag for FATE was found. We proposed the FATE and TPTE as the
potential CT antigen encoding genes and renamed them as FATE/
BJ-HCC-2 and TPTE/BJ-HCC-5.
Expression profile of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5
The mRNA expression profile of FATE/BJ-HCC-2 and TPTE/BJ-
HCC-5 was determined by RT–PCR. A series of tissues and cell
lines were examined, including normal tissues, tumour cell lines,
HCC and corresponding adjacent noncancerous tissues, gastric
cancer, non-small cell lung cancer, and colon cancer tissues.
Expression in normal tissues
For the detection of mRNA expression of FATE/BJ-HCC-2, there
were 16 different normal tissues of spleen, prostate, testis, ovary,
small intestine, colon, peripheral blood, heart, lung, liver, adrenal
gland, whole brain, kidney, pancreas, placenta, and skeletal muscle
being tested by RT–PCR (Olesen et al, 2001), FATE/BJ-HCC-2 was
strongly expressed in testis, and weakly detected in pancreatic
tissue, but undetectable in other tissues. Quantification of gene
expression revealed that the expression level of FATE/BJ-HCC-2
mRNA in the testis was five-fold higher than that in the pancreas.
For the detection of mRNA expression of TPTE/BJ-HCC-5, there
were 18 different normal tissues of spleen, thymus, testis, small
intestine, heart, lung, liver, brain, kidney, skin, stomach and
skeletal muscle, prostate, ovary, colon, peripheral blood, pancreas,
and placenta being tested by RT–PCR. Like the previous report
(Wu et al, 2001), the TPTE/BJ-HCC-5 mRNA was detected in the
testis only (Figure 1).
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Figure 1 Expression of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 mRNA in
16 normal tissues and eight cancer cell lines. Gel electrophoresis of RT–
PCR products shows FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 transcripts
expressed in testis, normal pancreas, and in some cancer cell lines. 1–16,
normal tissues: (1) brain, (2) heart, (3) kidney, (4) liver, (5) lung, (6)
placenta, (7) testis, (8) skeletal muscle, (9) colon, (10) ovary, (11)
leucocytes, (12) prostate, (13) small intestine, (14) spleen, (15) pancreas,
(16) thymus. (17–24), cancer cell lines: (17) breast carcinoma (GI-101),
(18) lung carcinoma (LX-1), (19) colon adenocarcinoma (CX-1), (20) lung
carcinoma (GI-117), (21) prostatic adenocarcinoma (PC3), (22) colon
adenocarcinoma (GI-112), (23), ovarian carcinoma (GI-102), (24),
pancreatic adenocarcinoma (GI-103).
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A panel of eight cancer cell lines (breast, G1-101; lung, LX-1 and
G1-117; colon, CX-1 and G1-112; prostate, PC3; ovary, G1-102; and
pancreas, G1-103) were tested. Both FATE/BJ-HCC-2 and TPTE/
BJ-HCC-5 were only expressed in prostate adenocarcinoma cell
line PC3 (Figure 1).
Expression in HCC tissues, adjacent noncancerous liver
tissues, cirrhosis, and other cancer tissues
FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 mRNA transcripts were
analysed for their expression in the samples of HCC tissues and
other cancer tissues. The FATE/BJ-HCC-2 mRNA transcript was
substantially expressed in 41 out of 62 HCC samples (66%), weakly
expressed in 12 out of 62 corresponding adjacent noncancerous
liver tissues, but not expressed in 10 liver samples of cirrhosis. The
average quantification of FATE/BJ-HCC-2 mRNA transcript was
120-fold higher in HCC tissues than in corresponding adjacent
noncancerous liver tissues. TPTE/BJ-HCC-5 mRNA transcript was
specifically expressed in 24 out of 62 HCC samples (39%), with no
detection in corresponding adjacent noncancerous liver tissues or
in cirrhotic liver samples. The average quantification of TPTE/BJ-
HCC-5 mRNA expression in tumour samples was approximately
comparable to that in the testis (Figure 2). To assess whether
FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 mRNA transcripts were
expressed in different histological types of tumours, their mRNA
expression in gastric cancer, colon cancer, and non-small cell lung
cancer tissues was tested. FATE/BJ-HCC-2 was expressed in 7%
(one out of 14) gastric cancer and 21% (three out of 14) colon
cancer samples, but not detected in 14 non-small cell lung cancer
samples. TPTE/BJ-HCC-5 was expressed in 36% (five out of 14)
non-small cell lung cancer samples, but not detected in 14 gastric
cancer and 14 colon cancer samples. Thus, both FATE/BJ-HCC-2
and TPTE/BJ-HCC-5 were expressed in normal testis and certain
types of cancers.
Isolation of full-length cDNA of BJ-HCC-2 and BJ-HCC-5
from HCC tissues
To further examine the RT–PCR results for FATE/BJ-HCC-2 and
TPTE/BJ-HCC-5, mRNA was extracted from HCC and correspond-
ing adjacent noncancerous liver tissues, then, analysed by North-
ern blot (Figure 3). The hybridisation signal of FATE/BJ-HCC-2
was shown as the size of 1.1kb, whereas the TPTE/BJ-HCC-5 was
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Figure 2 Expression of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 mRNA
transcripts in six paired samples of HCC and adjacent noncancerous liver
tissues. (A) Gel electrophoresis of RT–PCR products shows FATE/BJ-
HCC-2 and TPTE/BJ-HCC-5 mRNA transcripts in the paired HCC and
adjacent noncancerous liver tissue samples. RT–PCR for G3PDH was used
to monitor the quality of the mRNA samples. (B) Real-Time PCR
quantification of the expression of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5
mRNA transcripts in HCC tissues, paired adjacent noncancerous liver
tissues, cirrhotic liver tissues, gastric cancer, non-small cell lung cancer and
colon cancer tissue samples, normal testis, and pancreas.
ca ca adj adj
ca ca adj adj
FATE/BJ-HCC-2
FATE/BJ-HCC-2
G3PDH
G3PDH
A
TPTE/BJ-HCC-5
TPTE/BJ-HCC-5
B
Figure 3 Northern blot hybridisation of FATE/BJ-HCC-2 and TPTE/BJ-
HCC-5 in two pairs of HCC and adjacent noncancerous liver tissues
samples. In the Northern blot analysis, FATE/BJ-HCC-2 and TPTE/BJ-HCC-
5 mRNAs were only expressed in HCC tissues. The sizes of FATE/BJ-HCC-
2 and TPTE/BJ-HCC-5 mRNA transcripts were 1.1 and 2.5kb, respectively.
testis  ca adj        ca adj         ca adj        ca adj
TPTE/BJ-HCC-5A
TPTE/BJ-HCC-5B
Figure 4 Two isoforms of TPTE/BJ-HCC-5. A pair of specific primers
spanning the exon was designed and RT–PCR was performed using TPTE/
BJ-HCC-5 cDNA as the template. Gel electrophoresis of RT–PCR
products shows two TPTE/BJ-HCC-5 mRNA transcripts.
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consistent with the transcripts expressed in the testis. Gene-
specific primers (50-aat tta gct gcg cac agg gag gtg-30 and 50-tga gcg
tgt tgt ctg tgc aga gcg-30 for FATE/BJ-HCC-2; 50-cca caa tgg tcc acc
cac aaa tg-30 and 50-aac atg tgg cag ggt tgg aaa gaa c-30 for TPTE/
BJ-HCC-5) were designed to isolate the full-length cDNAs of
FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 from HCC. Sequence
analysis of the PCR product revealed that FATE/BJ-HCC-2 was
identical to FATE in cDNA sequence. However, TPTE/BJ-HCC-5
had two different sequences: one was identical to TPTE (1769bp)
and the other was 54bp shorter than TPTE. DNA alignment
indicated that the shorter TPTE/BJ-HCC-5 lacked an exon of 54bp
than TPTE. A pair of primers (50-cca caa tgg tcc acc cac aaa tg-30
and 50-agg tcg gca agg atg aga gtg aca tc-30) was then designed to
specifically amplify the cDNA fragments spanning the exon in all
samples by RT–PCR, and the TPTE/BJ-HCC-5 mRNA transcripts
were clearly shown as two bands simultaneously with the sizes of
390 and 336bp, respectively (Figure 4). The two PCR products
were sequenced and the results were those as predicted. Therefore,
TPTE/BJ-HCC-5 mRNA was expressed as two isoforms: one was
identical to TPTE, which encoded a protein of 551 amino acids,
called TPTE/BJ-HCC-5A, and the other was the alternative splice
variant of TPTE, which lacked the sequence of an exon (54bp) and
encoded a protein of 533 amino acids, lacking 18 amino acids at
the position of 41–58 in the NH2-terminus of TPTE, called TPTE/
BJ-HCC-5B (GenBank Accession Number AF495908). Both TPTE
isoforms were expressed in normal testis and cancers, with the
TPTE/BJ-HCC-5B being dominant in testis and the TPTE/BJ-HCC-
5A dominant in cancers. The deduced protein of FATE/BJ-HCC-2
was 183 amino acids in length with an isoelectric point of 9.6.
FATE/BJ-HCC-2 was predicted to be a soluble protein, but had no
signal peptide or motif with known function. There were three N-
myristoylation sites, one N-glycosylation site, one glycosamino-
glycan attachment site, and several kinase phosphorylation sites.
The TPTE/BJ-HCC-5 possessed four potential transmembrane
domains shown in hydropathy analysis and had an isoelectric
point of 8.5. There were two potential N-myristoylation sites, two
N-glycosylation sites, one tyrosine-specific protein phosphatases
active site, and several kinase phosphorylation sites in TPTE/BJ-
HCC-5 proteins. Both FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 may
undergo post-translational modifications. By chromosomal map-
ping, FATE/BJ-HCC-2 gene was located to chromosome Xq28,
where a lot of important CT antigen encoding genes are located,
such as MAGE family and NY-ESO-1 (De Plaen et al, 1994; Chen
et al, 1997a). By contrast, the TPTE/BJ-HCC-5 may be located in
the human chromosomes 13, 15, 21, 22, and Y, indicating that this
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Figure 5 Antibody response against FATE/BJ-HCC-2 and TPTE/BJ-
HCC-5 recombinant proteins in the sera of HCC patients. (A) Western
blot analysis of the positive sera against FATE/BJ-HCC-2 and TPTE/BJ-
HCC-5. The proteins of BJ-9 produced in E. coli and HCA587 produced in
insect cells were applied as irrelevant antigens in the WB assays. Lanes 1–6
correspond to lysates of E. coli (or insect cells) containing recombinant
proteins with 6 His tag mAb, purified recombinant proteins with 6 His
tag mAb, lysates of E. coli (or insect cells) containing recombinant proteins
with the positive sera, purified recombinant proteins with the positive sera,
lysates of E. coli (or insect cells) containing irrelevant protein controls with
the positive sera, and the negative controls of E. coli (or insect cells) with
the positive sera. Lanes 1, 3, 5, and 6 contained 100mg lysates of E. coli or
insect cells, whereas lanes 2 and 4 contained 5mg purified recombinant
proteins. Lane M corresponds to protein marker. (B) The standardisation
of ELISA. A standard serum obtained from a melanoma patient NW29 was
antibody positive against NY-ESO-1, with no detectable Ab against MAGE-
1. The titre of Ab against NY-ESO-1 was 1:6400 measured by indirect
ELISA. (C) Antibody titre against FATE/BJ-HCC-2 measured by indirect
ELISA. The three positive sera with the Ab against FATE/BJ-HCC-2
assessed by WB were measured by ELISA. The Ab titre were 1:6400,
1:1600, and 1:6400, respectively. (D) Antibody titre against FATE/BJ-
HCC-5 measured by indirect ELISA. The six positive sera with the Ab
against FATE/BJ-HCC-5 assessed by WB were measured by ELISA. The Ab
titre was in the range around 1:1600–1:3200.
b
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to be pseudogenes (Chen et al, 1999).
Expression and purification of FATE/BJ-HCC-2 and
TPTE/BJ-HCC-5 proteins
In order to analyse the antibody response to FATE/BJ-HCC-2 and
TPTE/BJ-HCC-5 proteins in HCC patients, we expressed the
respective recombinant proteins. The FATE/BJ-HCC-2 protein was
expressed in E.coli and accounted for 25% of the total protein.
TPTE/BJ-HCC-5 proteins was failed to be expressed in E. coli, but
expressed in insect cells using the Bac-to-Bac expression system.
The expression level was 0.2mg in the cultures of 10
7 insect cells.
Both recombinant proteins contained 6 His tag to facilitate
protein identification.
A survey of sero-reactivity against FATE/BJ-HCC-2 and
TPTE/BJ-HCC-5 proteins in HCC patients
Sero-reactivity was firstly screened using WB analysis. In the 62
sera collected from HCC patients, there were three sera reactive to
FATE/BJ-HCC-2 protein and six sera to TPTE/BJ-HCC-5 proteins
(Figure 5A). As the specificity controls, BJ-9 proteins expressed in
E. coli and HCA587 expressed in insect cells were applied as
irrelevant proteins in WB using the sera Ab positive to FATE/BJ-
HCC-2 and FATE/BJ-HCC-5, respectively. The sero-reactivity was
negative to BJ-9 and HCA587. In the 18 sera collected from normal
individuals, none was reactive to FATE/BJ-HCC-2 or FATE/BJ-
HCC-5 protein. The WB analysis was repeated twice and the same
results were obtained. To further confirm the Ab response and
semiquantitate the Ab titre, indirect ELISA was applied. The ELISA
was optimised using the serum of melanoma patient NW29 as the
standard serum, in which the Ab against NY-ESO-1 was positive,
but with no detectable Ab against MAGE-1 (Figure 5B). In the
three positive sera with the Ab against FATE/BJ-HCC-2, the Ab
titre was 1:6400, 1:1600, and 1:6400, respectively (Figure 5C).
In the six positive sera with the Ab against FATE/BJ-HCC-5, the
Ab titre was in the range around 1:1600–1:3200 (Figure 5D).
The Ab was only detected in the HCC patients whose resected
tumours expressed the FATE/BJ-HCC-2 or TPTE/BJ-HCC-5
mRNA, not in the HCC patients bearing FATE/BJ-HCC-2 or
TPTE/BJ-HCC-5 mRNA negative tumours. Therefore, the actual
frequency of antibody response against FATE/BJ-HCC-2 and
TPTE/BJ-HCC-5 proteins was 7.3% (three out of 41) and 25.0%
(six out of 24), respectively, in HCC patients bearing respective
gene transcripts.
DISCUSSION
In this study, we targeted known testis-specific genes to investigate
the possibility that some of these would be the CT antigen-
encoding genes by database analysis. The selected candidates were
assayed for their mRNA expression profile in normal tissues,
tumour cell lines, HCC tissues and corresponding adjacent
noncancerous liver tissues, and the tissues of gastric cancer,
non-small cell lung cancer, and colon cancer. Two known testis-
specific genes, FATE and TPTE, were identified to be restrictedly
expressed in different cancers and normal testis. The FATE was
also weakly expressed in normal pancreatic tissue. The TPTE gene
was originally reported to encode a protein of 551 amino acids
(Chen et al, 1999). We identified an alternative splice variant of
TPTE cDNA, which was otherwise identical to TPTE except lacking
an exon (54bp), encoding a protein of 533 amino acids. Its
sequence at the exon–intron junction is consistent with the AG-
GT rule. For distinction, we called the TPTE as TPTE/BJ-HCC-5A
and the variant as the TPTE/BJ-HCC-5B. These two isoforms of
TPTE cDNA might be caused by different splicing, and the splicing
machinery might be regulated by different factors that resulted in
the TPTE/BJ-HCC-5B dominantly expressed in testis and the
TPTE/BJ-HCC-5A dominantly expressed in cancer tissues. Ser-
ological survey of 62 sera collected from HCC patients revealed
that 4.8% (three out of 62) and 9.6% (six out of 62) had antibody
response to FATE/BJ-HCC-2 protein and TPTE/BJ-HCC-5 pro-
teins, respectively. Regarding to the fact that Ab response was only
detected in the patients bearing FATE/BJ-HCC-2 or TPTE/BJ-HCC-
5 mRNA
þHCC, the correct frequency of Ab response against
FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 proteins was 7.3% (three out
of 41) and 25.0% (six out of 24), respectively. Thus, the FATE/BJ-
HCC-2 and TPTE/BJ-HCC-5 proteins are immunogenic and can be
classified as the novel CT antigens.
Apart from a few CT antigens, such as SCP-1, a meiosis protein
(Heyting, 1996; Tureci et al, 1998), SSX, the transcriptional
repressors (Brett et al, 1997), OY-TES-1, a proacrosin binding
protein (Baba et al, 1994), HOM-TES-85, a novel leucine zipper
protein, the biological function of the majority of CT antigens is
unknown. FATE/BJ-HCC-2 was found to be coexpressed with SRY,
which functions as a genetic switch that directs the development of
the indifferent gonad from a female to a male pathway, in the 7-
week-old fetal testis and might play a role in early testicular
differentiation (Olesen et al, 2001). The expression of FATE/BJ-
HCC-2 is regulated by steroidogenic factor (SF-1) and Wilms’
tumour gene 1 (WT1) and involved in gamesomeness. As SF-1 and
WT1 are involved in the development of tumour (Bamberger et al,
1996; Menke et al, 1998; Lopez et al, 1999; Sugiyama, 2001; Aylwin
et al, 2001; Oka et al, 2002), the FATE/BJ-HCC-2 may also be
involved in tumourigenesis. The TPTE/BJ-HCC-5 contributes to
the terminal stages of spermatocyte differentiation (Wu et al,
2001). The TPTE/BJ-HCC-5A and TPTE/BJ-HCC-5B share sig-
nificant homology with tumour suppressor protein PTEN, which is
a phosphatidylinositol phospholipid phosphatase (Maehama et al,
1998). TPTE/BJ-HCC-5A and TPTE/BJ-HCC-5B are also phospho-
lipid phosphatases and are localised on the membrane of the Golgi
complex (Wu et al, 2001). Although lacking 18 amino acids in the
NH2-terminus, the altered TPTE/BJ-HCC-5B has all the important
functional domains of TPTE/BJ-HCC-5A. In view of the fact that
many tumour-derived missense mutations were observed in PTEN
resulting in cell cycle progression and inhibition of apoptosis, the
TPTE/BJ-HCC-5A and TPTE/BJ-HCC-5B may be involved in the
survival of tumour cells. TPTE/BJ-HCC-5A and TPTE/BJ-HCC-5B
contribute to the terminal stages of spermatocyte differentiation
(Wu et al, 2001). With respect to the fact that CT antigen proteins
are expressed in both testis and cancers, they may have functional
similarities in the spermatogenesis and tumourigenesis. The
functional clues of FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 make
them the molecular models for analysing the shared mechanism
between gametogenesis and tumourigenesis.
In conclusion, both FATE/BJ-HCC-2 and TPTE/BJ-HCC-5 are
novel CT antigens. Further analysis needs to be carried out to
investigate their capacity in the elicitation of specific cell-mediated
immunity to determine if they are potential candidates for tumour
immunotherapy.
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